Paulo F. Costa - 17 May 2023 Form 4/A - Amendment Insider Report for CorMedix Inc. (CRMD)

Reporting relationship: Director
Issuer ticker: CRMD
Reported as of: 17 May 2023
Net transaction value: +$46,500
SEC form: 4/A - Amendment
Accepted by SEC: 18 May 2023, 18:26:03 UTC
Original report date: 17 May 2023
Prior SEC filing: 18 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Paulo F. Costa

Key filing fact

Paulo F. Costa filed Form 4/A - Amendment for CorMedix Inc. (CRMD) on 18 May 2023.

Key facts

This page summarizes Paulo F. Costa's Form 4/A - Amendment filing for CorMedix Inc. (CRMD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 May 2023, 18:26.

Change

Previous filing in this sequence was filed on 18 Jan 2023.
Current net transaction value: +$46,500.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRMD transaction

Common Stock

Purchase

Transaction value: $46,500
Shares: +10,000
Change %
Price: $4.65
Shares after: 10,000
Date: 17 May 2023
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On May 17, 2023, the reporting person filed a Form 4 which inadvertently included Transaction Code "A". The original Form 4 should have indicated Transaction Code "P". The reporting person has filed this amendment to restate the transaction with the correct Transaction Code.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.605 to $4.65, inclusive. The reporting person undertakes to provide CorMedix Inc., any security holder of CorMedix Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.